IntelGenx Reschedules Third Quarter 2022 Conference Call Due to Technical Issues Experienced Today by Webcast Vendor
IntelGenx Technologies Corp. (TSX:IGX) has rescheduled its third quarter 2022 conference call to November 11, 2022, at 8:00 a.m. ET, moving it from the original date. This call will be critical for investors to evaluate the company's latest financial performance and operational updates. The event can be accessed via phone or through a live broadcast on IntelGenx’s website. The company, noted for its innovative pharmaceutical film technologies, continues to focus on addressing unmet medical needs through its advanced product pipeline.
- Rescheduling allows for a more comprehensive financial overview for shareholders.
- The delay in the conference call may signal potential issues with Q3 results.
SAINT LAURENT, Quebec, Nov. 10, 2022 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that its third quarter 2022 conference call, originally scheduled for today, will now be held tomorrow (Friday, November 11, 2022) before market open.
| REVISED: Third Quarter 2022 Results Conference Call Details | |
| Date: | Friday, November 11, 2022 |
| Time: | 8:00 a.m. ET |
| Live Call: | 1- 877-545-0523 (Canada and the United States) |
| 1- 973-528-0016 (International) | |
| Access Code: | 383330 |
The call will also be broadcast live and archived on the Company's website at www.intelgenx.com under "Webcasts" in the Investors section.
About IntelGenx
IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.
IntelGenx’s superior film technologies, including VersaFilm®, DisinteQ™, VetaFilm™ and transdermal VevaDerm™, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx’s innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.
IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. For more information, visit www.intelgenx.com.
Forward-Looking Information and Statements
This document may contain forward-looking information about IntelGenx's operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx's plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx's actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx's annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities at www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.
Source: IntelGenx Technologies Corp.
For IntelGenx:
Stephen Kilmer
Investor Relations
(647) 872-4849
stephen@kilmerlucas.com
Or
Andre Godin, CPA, CA
President and CFO
IntelGenx Corp.
(514) 331-7440 ext 203
andre@intelgenx.com
FAQ
When is IntelGenx's third quarter 2022 results conference call?
How can I access the IntelGenx conference call on November 11, 2022?
What is the significance of IntelGenx’s revised conference call date?
What technologies does IntelGenx specialize in?
Where can I find the webcast of IntelGenx's conference call?
